Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.49 |
| ▸ | BRD4 | O60885 | 6/20 | 0.39 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.37 |
| ▸ | FTO | Q9C0B1 | 7/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | BRD2 | P25440 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16110687 | 0.82 | ERN1 (0.54) | ERN1BRD4ATAD2FTOBRD2 | |
| SCHEMBL16110765 | 0.78 | ERN1 (0.50) | ERN1BRD4BRD2 | |
| SCHEMBL16110737 | 0.76 | ERN1 (0.46) | ERN1BRD4ATAD2FTOMLYCD | |
| SCHEMBL16110579 | 0.75 | ERN1 (0.56) | ERN1BRD4ATAD2BRD2CREBBP | |
| SCHEMBL16110501 | 0.75 | ERN1 (0.56) | ERN1BRD4ATAD2BRD2CREBBP | |
| SCHEMBL20362753 | 0.73 | ERN1 (0.56) | ERN1BRD4ATAD2FTOBRD2 | |
| SCHEMBL28358908 | 0.72 | GAA (0.36) | ERN1 | |
| SCHEMBL16140186 | 0.71 | ERN1 (0.52) | ERN1BRD4ATAD2BRD2CREBBP | |
| SCHEMBL16110947 | 0.71 | ERN1 (0.52) | ERN1BRD4ATAD2FTOBRD2 | |
| SCHEMBL16225411 | 0.71 | ERN1 (0.54) | ERN1BRD4FTO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2978759-B1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9255089-B2 | Benzimidazolone derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-9255089-B2 | Benzimidazolone derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20160031868-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031868-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031868-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20140296246-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296246-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296246-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031868-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | ERN1 1040/4885BRD4 1/4885ATAD2 325/4885 |
| US-20140296246-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | ERN1 1040/4885BRD4 1/4885ATAD2 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.